ライフサイエンスコーパス: nifurtimox

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ei infection in mice when used together with nifurtimox.

2 can immigrants, who underwent treatment with nifurtimox (8-10 mg/kg in 3 daily doses for 12 weeks) fr

3 ty, approximately 1000-fold more potent than nifurtimox against in vitro Trypanosoma brucei with very

4 Nifurtimox and benznidazole are the front-line drugs use

5 The current chemotherapy is limited only to nifurtimox and benznidazole, two drugs that have poor ef

6 cells were then treated with combinations of nifurtimox and BSO and evaluated for viability using MTT

7 Furthermore, the combination of nifurtimox and BSO demonstrated significant synergistic

8 l and clinical studies of the combination of nifurtimox and BSO in patients with neural tumors are wa

9 Previous studies have identified nifurtimox and buthionine sulfoximine (BSO) as effective

10 ll neural tumor cell lines were sensitive to nifurtimox, and IC50 values ranged from approximately 20

11 We found that nifurtimox appeared to use several membrane transporters

12 Current treatments based on benznidazole and nifurtimox are expensive, ineffective, and toxic.

13 s that the front-line drugs benznidazole and nifurtimox are more effective against the acute stage in

14 one are more effective than benznidazole and nifurtimox as curative treatments, particularly for acut

15 ly the drug transport mechanisms utilised by nifurtimox at the BBB, but also the impact of nifurtimox

16 combination therapies (CTs) on radiolabelled-nifurtimox delivery in an in vitro model of drug accumul

17 ifurtimox at the BBB, but also the impact of nifurtimox-eflornithine combination therapy (NECT) and o

18 The recent development of nifurtimox-eflornithine combination therapy (NECT) has b

19 , the World Health Organization approved the nifurtimox-eflornithine combination therapy for the trea

20 andard therapeutic options, benznidazole and nifurtimox, have significant side effects and are only e

21 is the first study to evaluate tolerance of nifurtimox in US patients with CD.

22 Nifurtimox is 1 of only 2 medications available for trea

23 echanism has important implications, because nifurtimox is currently undergoing phase III clinical tr

24 Eflornithine combined with nifurtimox is the first-line treatment for late-stage T

25 Eflornithine, alone or combined with nifurtimox, is being used increasingly as first-line the

26 sted the effectiveness of benznidazole (BZ), nifurtimox (NFX), other prospective drugs in intermitten

27 hine caused no change in the accumulation of nifurtimox, nor did the addition of clinically relevant

28 al, biochemical process to those targeted by nifurtimox or its metabolites in the parasites.

29 t doses of the other anti-HAT drugs suramin, nifurtimox or melarsoprol, but a significant increase wa

30 Nifurtimox produces frequent side effects, but the major

31 ogue showed very limited cross-resistance to nifurtimox-resistant cells and vice versa.

32 Nifurtimox treatment inhibited ERK phosphorylation and i

33 T. cruzi infection followed by nifurtimox treatment rescue was used to immunize CD4, CD

34 to measure the induction of apoptosis after nifurtimox treatment.

35 ll viability before and after treatment with nifurtimox using MTT assays.

36 gas' disease are limited to benznidazole and nifurtimox, which have been associated with low cure rat

37 We hypothesized that nifurtimox would be effective against other neural tumor

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。